168 related articles for article (PubMed ID: 18951621)
1. Anti-IL-5 (mepolizumab) therapy does not alter IL-5 receptor alpha levels in patients with eosinophilic esophagitis.
Conus S; Straumann A; Simon HU
J Allergy Clin Immunol; 2009 Jan; 123(1):269; author reply 269-70. PubMed ID: 18951621
[No Abstract] [Full Text] [Related]
2. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels.
Stein ML; Villanueva JM; Buckmeier BK; Yamada Y; Filipovich AH; Assa'ad AH; Rothenberg ME
J Allergy Clin Immunol; 2008 Jun; 121(6):1473-83, 1483.e1-4. PubMed ID: 18410960
[TBL] [Abstract][Full Text] [Related]
3. Mepolizumab does not alter levels of eosinophils, T cells, and mast cells in the duodenal mucosa in eosinophilic esophagitis.
Conus S; Straumann A; Bettler E; Simon HU
J Allergy Clin Immunol; 2010 Jul; 126(1):175-7. PubMed ID: 20542323
[No Abstract] [Full Text] [Related]
4. Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders.
Olivieri B; Tinazzi E; Caminati M; Lunardi C
Immunol Allergy Clin North Am; 2020 Nov; 40(4):649-665. PubMed ID: 33012326
[TBL] [Abstract][Full Text] [Related]
5. Mepolizumab and eosinophil-mediated disease.
Walsh GM
Curr Med Chem; 2009; 16(36):4774-8. PubMed ID: 19929788
[TBL] [Abstract][Full Text] [Related]
6. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis.
Assa'ad AH; Gupta SK; Collins MH; Thomson M; Heath AT; Smith DA; Perschy TL; Jurgensen CH; Ortega HG; Aceves SS
Gastroenterology; 2011 Nov; 141(5):1593-604. PubMed ID: 21835135
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of interleukin-5 for the treatment of eosinophilic diseases.
Corren J
Discov Med; 2012 Apr; 13(71):305-12. PubMed ID: 22541618
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media.
Iino Y; Takahashi E; Ida S; Kikuchi S
Auris Nasus Larynx; 2019 Apr; 46(2):196-203. PubMed ID: 30122651
[TBL] [Abstract][Full Text] [Related]
9. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis.
Stein ML; Collins MH; Villanueva JM; Kushner JP; Putnam PE; Buckmeier BK; Filipovich AH; Assa'ad AH; Rothenberg ME
J Allergy Clin Immunol; 2006 Dec; 118(6):1312-9. PubMed ID: 17157662
[TBL] [Abstract][Full Text] [Related]
10. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial.
Straumann A; Conus S; Grzonka P; Kita H; Kephart G; Bussmann C; Beglinger C; Smith DA; Patel J; Byrne M; Simon HU
Gut; 2010 Jan; 59(1):21-30. PubMed ID: 19828470
[TBL] [Abstract][Full Text] [Related]
11. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700.
Kim YJ; Prussin C; Martin B; Law MA; Haverty TP; Nutman TB; Klion AD
J Allergy Clin Immunol; 2004 Dec; 114(6):1449-55. PubMed ID: 15577851
[TBL] [Abstract][Full Text] [Related]
12. [Anti-interleukin-5 therapy for eosinophilic diseases].
Simon D; Braathen LR; Simon HU
Hautarzt; 2007 Feb; 58(2):122, 124-7. PubMed ID: 17221241
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody.
Smith DA; Minthorn EA; Beerahee M
Clin Pharmacokinet; 2011 Apr; 50(4):215-27. PubMed ID: 21348536
[TBL] [Abstract][Full Text] [Related]
14. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ
J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242
[TBL] [Abstract][Full Text] [Related]
15. Mepolizumab in the treatment of severe eosinophilic asthma.
Fainardi V; Pisi G; Chetta A
Immunotherapy; 2016; 8(1):27-34. PubMed ID: 26653083
[TBL] [Abstract][Full Text] [Related]
16. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
17. Eosinophils and interleukin-5: the debate continues.
Kay AB; Menzies-Gow A
Am J Respir Crit Care Med; 2003 Jun; 167(12):1586-7. PubMed ID: 12796050
[No Abstract] [Full Text] [Related]
18. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
Roufosse F; de Lavareille A; Schandené L; Cogan E; Georgelas A; Wagner L; Xi L; Raffeld M; Goldman M; Gleich GJ; Klion A
J Allergy Clin Immunol; 2010 Oct; 126(4):828-835.e3. PubMed ID: 20810155
[TBL] [Abstract][Full Text] [Related]
19. Current update on eosinophilic lung diseases and anti-IL-5 treatment.
Samitas K; RĂ¥dinger M; Bossios A
Recent Pat Antiinfect Drug Discov; 2011 Sep; 6(3):189-205. PubMed ID: 21824072
[TBL] [Abstract][Full Text] [Related]
20. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.
Nair P; Pizzichini MM; Kjarsgaard M; Inman MD; Efthimiadis A; Pizzichini E; Hargreave FE; O'Byrne PM
N Engl J Med; 2009 Mar; 360(10):985-93. PubMed ID: 19264687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]